TW202348622A - sPD-1變異體 – FC融合蛋白 - Google Patents

sPD-1變異體 – FC融合蛋白 Download PDF

Info

Publication number
TW202348622A
TW202348622A TW112132395A TW112132395A TW202348622A TW 202348622 A TW202348622 A TW 202348622A TW 112132395 A TW112132395 A TW 112132395A TW 112132395 A TW112132395 A TW 112132395A TW 202348622 A TW202348622 A TW 202348622A
Authority
TW
Taiwan
Prior art keywords
seq
spd
variant
domain
fusion protein
Prior art date
Application number
TW112132395A
Other languages
English (en)
Chinese (zh)
Inventor
阿曼都 J 基耶西亞
踏德 A 阿基雷拉
米哈利斯 S 卡利歐利斯
鈺 繆
考史克 贊卡爾
欣 張
Original Assignee
李蘭 史丹佛學院理事會
美商艾克索生物製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 李蘭 史丹佛學院理事會, 美商艾克索生物製藥有限公司 filed Critical 李蘭 史丹佛學院理事會
Publication of TW202348622A publication Critical patent/TW202348622A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112132395A 2018-09-14 2019-09-12 sPD-1變異體 – FC融合蛋白 TW202348622A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US62/731,488 2018-09-14
US201962888320P 2019-08-16 2019-08-16
US62/888,320 2019-08-16

Publications (1)

Publication Number Publication Date
TW202348622A true TW202348622A (zh) 2023-12-16

Family

ID=68211179

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112132395A TW202348622A (zh) 2018-09-14 2019-09-12 sPD-1變異體 – FC融合蛋白
TW108133070A TWI815964B (zh) 2018-09-14 2019-09-12 sPD-1變異體–FC融合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW108133070A TWI815964B (zh) 2018-09-14 2019-09-12 sPD-1變異體–FC融合蛋白

Country Status (11)

Country Link
US (2) US11498955B2 (cg-RX-API-DMAC7.html)
EP (1) EP3850003A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021535761A (cg-RX-API-DMAC7.html)
KR (1) KR20210058902A (cg-RX-API-DMAC7.html)
CN (1) CN112969710A (cg-RX-API-DMAC7.html)
AU (1) AU2019338416A1 (cg-RX-API-DMAC7.html)
CA (1) CA3109983A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ774126A (cg-RX-API-DMAC7.html)
SG (1) SG11202101904UA (cg-RX-API-DMAC7.html)
TW (2) TW202348622A (cg-RX-API-DMAC7.html)
WO (1) WO2020056085A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
US20230414660A1 (en) * 2020-11-13 2023-12-28 Ludwig Institute For Cancer Research Ltd Pd-1 decoy variants for immunotherapy
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
WO2022187488A2 (en) * 2021-03-03 2022-09-09 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
US20220387488A1 (en) 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
EP4346875A4 (en) * 2021-05-28 2025-04-16 Akso Biopharmaceutical, Inc. BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15
KR20230044131A (ko) * 2021-09-24 2023-04-03 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
CN103261217B (zh) * 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
US20150368316A1 (en) * 2013-02-07 2015-12-24 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
US10844392B2 (en) * 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
PL3368572T5 (pl) * 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
WO2019241758A1 (en) * 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof

Also Published As

Publication number Publication date
WO2020056085A1 (en) 2020-03-19
EP3850003A1 (en) 2021-07-21
US20230131056A1 (en) 2023-04-27
CA3109983A1 (en) 2020-03-19
NZ774126A (en) 2023-05-26
AU2019338416A1 (en) 2021-04-29
KR20210058902A (ko) 2021-05-24
US11498955B2 (en) 2022-11-15
US20200181231A1 (en) 2020-06-11
CN112969710A (zh) 2021-06-15
JP2021535761A (ja) 2021-12-23
SG11202101904UA (en) 2021-04-29
TWI815964B (zh) 2023-09-21
TW202023604A (zh) 2020-07-01

Similar Documents

Publication Publication Date Title
TWI815964B (zh) sPD-1變異體–FC融合蛋白
KR102928276B1 (ko) IL-15/IL-15Rα 이종이량체 Fc 융합 단백질 및 이의 용도
KR102909650B1 (ko) 종양 특이적 세포 고갈에 대한 항-cd25
JP7273453B2 (ja) IL-15/IL-15RアルファFc融合タンパク質およびPD-1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
US20200140512A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
KR20210010862A (ko) IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
EP4587123A1 (en) Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
AU2022358565A1 (en) Immunocytokine containing il-21r mutein
CN116162168A (zh) 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
WO2022263507A1 (en) Novel tri-specific binding molecules
JP2023537605A (ja) sBCMAバリアントおよびそのFC融合タンパク質
RU2785993C2 (ru) ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC
CN121100134A (zh) 一种靶向人cd16和肿瘤抗原的多特异性抗体
CN121285385A (zh) 能够与ox40结合的抗体、其变体及其用途
HK40053326A (en) Spd-1 variant - fc fusion proteins
NZ796397A (en) sPD-1 variant - Fc fusion proteins
RU2827796C2 (ru) Гетеродимерные слитые белки ИЛ-15/ИЛ-15Рα - Fc и их применение
CN119451985A (zh) 在组合疗法中能够结合cd27的结合剂
WO2025191144A1 (en) Conjugates of egfr-specific antigen binding proteins and cytokines
HK40009952B (en) Binding molecules that modulate a biological activity expressed by a cell